X
<

Where Sanofi Stands after the 3Q17 Results

PART:
1 2 3 4 5 6 7 8
Part 6
Where Sanofi Stands after the 3Q17 Results PART 6 OF 8

Behind Sanofi’s Established Product Performance in 3Q17

Established prescription products

Sanofi’s (SNY) general medicines and emerging markets businesses include established prescription products, generic products, and revenues from emerging markets. For 3Q17, revenues from established prescription products fell 6.5% YoY (year-over-year) at constant exchange rates to 2.26 billion euros.

Behind Sanofi’s Established Product Performance in 3Q17

Interested in FVD? Don't miss the next report.

Receive e-mail alerts for new research on FVD

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The fall in revenues in 3Q17 was driven by lower sales of Plavix, Lovenox, Renagel, Aprovel, Allegra, Myslee, Targocid, and few other drugs, partially offset by a rise in Depakine sales.

Lovenox

Lovenox’s revenues rose 5.4% at constant exchange rates to 370 million euros in 3Q17, driven by lower sales in Europe and the rest of the world, partially offset by a rise in US sales and revenues from emerging markets. Sales from European markets fell 10.9% to 220 million euros in 3Q17 due to competition from other products.

Plavix

Plavix revenues fell 4.7% at constant exchange rates to 358 million euros during 3Q17, driven by a 7.5% fall in European sales to 37 million euros and a 28.2% fall in sales from rest of the world, excluding emerging markets and European markets. Sales from emerging markets rose 5% to 254 million euros.

Renagel and Renvela

Renagel and Renvela reported a combined 35.1% fall in revenues at constant exchange rates to 153 million euros for 3Q17. This decline was due to lower sales in US markets, European markets, and rest of the world, partially offset by a rise in revenues from emerging markets.

Notably, the First Trust Value Line Dividend ETF (FVD) has 6.7% of its total investments in the healthcare Sector, with 0.5% in Sanofi ADR (SNY), 0.5% in GlaxoSmithKline ADR (GSK), 0.5% in Merck (MRK), and 0.5% in Novartis ADR (NVS).

X

Please select a profession that best describes you: